Skip to main content
Log in

Study of a GABAc receptor antagonist on sleep-waking behavior in rats

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract.

Rationale: γ-Aminobutyric acid (GABA) is the main inhibitory transmitter of the brain. The involvement of GABAA and GABAB receptors in sleep-waking processes is well established. Objectives: This research studied the influence of GABAC receptors. Methods: The rats were randomly infused in the fourth ventricle with vehicle and 25, 50, and 100 µg (1,2,5,6,-tetrahydropyridine)-methylphosphinic acid (TPMPA), a specific antagonist of GABAC receptors. Results: Principally at 50 µg, the molecule induced an increase of waking from 44.7% to 61.7% (P<0.003), which was the consequence of enhancement of both active and quiet wakefulness. Total slow wave sleep was decreased, particularly the slow-wave stage from 39% to 27.7% (P<0.02). Paradoxical sleep was also decreased from 14.5% to 9.1% (P<0.01). Conclusions: GABAC receptors are also involved in sleep-waking regulation. Since the sensitivity of GABAC receptors to GABA is much higher than that of GABAA and GABAB receptors, GABAC receptor modulators could be potential medications acting at low doses with fewer side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnaud, C., Gauthier, P. & Gottesmann, C. Study of a GABAc receptor antagonist on sleep-waking behavior in rats. Psychopharmacology 154, 415–419 (2001). https://doi.org/10.1007/s002130000653

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002130000653

Navigation